Microparticles and microvascular dysfunction following STEMI
Research type
Research Study
Full title
The role of circulating microparticles as determinants of microvascular thrombosis and left ventricular recovery following ST-elevation myocardial infarction (Student Study)
IRAS ID
195859
Contact name
Roby Rakhit
Contact email
Sponsor organisation
University College London Hospitals NHS Foundation Trust
Duration of Study in the UK
2 years, 4 months, 1 days
Research summary
Almost 200,000 people suffer heart attacks in the UK each year, caused by the blockage of one of the arteries that supply blood to the heart muscle. Established standard treatment involves immediate restoration of blood flow by performing a coronary angioplasty procedure followed by medication to protect the heart. Despite this, about 25% of patients experience symptoms of heart failure due to irreversible damage to the heart muscle. This results in increased risk of death and more chance of hospital admission. \n\nThis study aims to understand the mechanisms behind this damage and to identify markers to predict risk of irreversible heart damage. We will study patients with heart attack and compare them to patients attending for planned angioplasty for angina. We will measure blood levels of microparticles (cell fragments that may cause ongoing injury and act as marker of heart damage), take pressure and flow measurements from within the heart artery, perform MRI scans to identify heart damage and test blood vessel wall function non-invasively. \n\nWe hope to identify a new marker of high risk that could be used in clinical practice to identify patients requiring treatment with more potent blood thinning medication to prevent long-term heart damage.\n\n
REC name
London - Hampstead Research Ethics Committee
REC reference
16/LO/1475
Date of REC Opinion
5 Oct 2016
REC opinion
Further Information Favourable Opinion